Sophia Genetics

Latin America’s largest medical diagnostic company taps into SOPHiA’s new multimodal solution to fight cancer, fostering a new Data-Driven Medicine era

São Paulo, Brazil, July 23, 2020: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today the signature of a Trial Match agreement with Dasa, the largest medical diagnostic company in Latin America. The group chose the SOPHiA Platform to lead the region toward an extensive approach to Data-Driven Medicine powered by the world’s first integrated multimodal …

Latin America’s largest medical diagnostic company taps into SOPHiA’s new multimodal solution to fight cancer, fostering a new Data-Driven Medicine era Read More »

SOPHiA GENETICS Reaches New Analytical Heights with its Whole Exome Solution

SOPHiA Whole Exome Solution (WES) now includes accurate CNV detection, making it a powerful application for healthcare professionals in their fight against rare diseases. Houston, Texas, USA – 18th October 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version …

SOPHiA GENETICS Reaches New Analytical Heights with its Whole Exome Solution Read More »

SOPHiA GENETICS Expands Executive Team with a Chief Marketing Officer and New Chief Information Officer

Lausanne, Switzerland, and Boston, United States, September 19, 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly specialized experience from key players in the health tech industry. …

SOPHiA GENETICS Expands Executive Team with a Chief Marketing Officer and New Chief Information Officer Read More »

Spearheading a paradigm shift in robotic surgery: Michael Friedrich discusses Dexter at Viszeralchirurgische Tage 2019 in Bonn, Germany

Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) inrelapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland, August 6, 2019– ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine, today announced they …

Spearheading a paradigm shift in robotic surgery: Michael Friedrich discusses Dexter at Viszeralchirurgische Tage 2019 in Bonn, Germany Read More »